The owner of a major licensed marijuana cultivation company in Arkansas is lobbying against a ballot initiative to legalize medical cannabis in Mississippi. Advocates allege that this individual aims to undermine the initiative to gain a competitive advantage in the market once legalization occurs.
Stephen LaFrance, who heads Natural State Medicinals in Arkansas, hired lobbyists in Jackson, Mississippi, shortly after the state announced that reform advocates had secured enough valid signatures for their legalization measure to qualify for the November ballot. The Mississippi Center for Public Policy first highlighted this lobbying activity. According to the center, LaFrance “is seeking to kill Initiative 65, which would establish a medical cannabis program in Mississippi and require the state Department of Health to oversee it.”
Concerns About Initiative 65
LaFrance’s attorney, Alex Gray, conveyed his client’s opposition to Initiative 65, which would permit patients with debilitating medical conditions to access cannabis following a physician’s recommendation. Gray emphasized that LaFrance is not against legalization itself but has concerns regarding the initiative’s language, describing it as “irresponsible” and not representative of a genuine medical program.
“We are advocating for a legitimate medical marijuana program with pharmaceutical-grade medicine,” Gray said. He indicated that LaFrance is hopeful for a framework that would benefit both patients and the state, asserting that the current proposal is difficult to regulate effectively.
Proposed Changes to Cannabis Legislation
LaFrance seeks to implement changes such as licensing caps for cannabis businesses and a merit-based licensing system. Such reforms could potentially aid LaFrance when he eventually enters the Mississippi market. Gray, representing cannabis cultivators and dispensaries, remarked on LaFrance’s successful track record in Arkansas, stressing that his client is not guaranteed success by advocating for a better-regulated medical marijuana framework.
However, should Initiative 65 fail, the timeline for potential legalization may be extended considerably, as the legislature has historically shown little interest in pursuing this reform. Advocates suspect that some lawmakers are attempting to introduce alternative resolutions that could appear alongside the primary measure on the ballot, should those proposals gain legislative approval.
If an alternative resolution is included on the ballot, it could create voter confusion and divide the vote. The language in these alternatives may also be vague and open to interpretation, meaning that if one passes instead of the initiative, legislators might implement a more restrictive program.
Industry Reactions
Jamie Grantham, communications director for Mississippians for Compassionate Care, expressed concern over the situation. “These alternatives would extinguish any hope for the medical marijuana access patients need,” she stated, condemning the involvement of Mississippi lobbyists working against a program aimed at assisting patients with serious medical conditions.
Gray responded to accusations by reiterating LaFrance’s intent to promote a genuine medical marijuana program that necessitates pharmaceutical-grade cannabis. He indicated that LaFrance is interested in participating in any merit-based program that may arise.
Matthew Schweich, deputy director of the Marijuana Policy Project, voiced strong opposition to placing alternative initiatives on the Mississippi ballot, warning that such action risks delaying critical legal protections for medical marijuana patients in the state. He emphasized that Initiative 65 represents a thoroughly crafted medical marijuana policy with no valid reason to jeopardize its success.
Requests for comment sent to Gray regarding alternative resolutions and statutory medical cannabis bills introduced in Mississippi were not returned, nor did lobbyists from the firm Thompson & Associates, LLC respond to inquiries.
